Futura Medical PLC's (LON:FUM) James Barder tells Proactive London's Andrew Scott they've seen little impact from the coronavirus lockdown and that regulatory submissions for its erectile dysfunction treatment remain on track.
The treatment is MED3000 - a fast-acting gel that will be targeted at men for whom the current treatments don’t work.
Barder says a second pre-submission meeting with the US Food & Drug Administration has been now set.
